Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2021-06-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well obinutuzumab works in combination with ibrutinib in
treating patients with mantle cell lymphoma that has returned (relapsed) or that does not
respond to treatment (refractory). Obinutuzumab binds to a protein called cluster of
differentiation (CD)20, which is found on B cells and some types of leukemia and lymphoma
cells and help the immune system kill cancer cells. Ibrutinib blocks a protein called
Bruton's tyrosine kinase (BTK), which may help keep cancer cells from growing. Giving
obinutuzumab in combination with ibrutinib may kill more cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Genentech, Inc. National Cancer Institute (NCI) Oregon Health and Science University